ERBB2 and neoplasm: To maintain breast CSCs, WNT/β-catenin/TCF signaling can promote HER2-bypassing signal transduction through IRS1-mediated ErbB-PI3K-AKT signaling, thereby inducing tumor resistance to trastuzumab.